Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Benefits of perioperative radiotherapy for liver cancer with a high risk of recurrence are investigated in research.

2.

Childhood cancer survivors face new health problems later in life, study shows

3.

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

4.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

5.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot